Understanding Shingrix Efficacy-by-Age Through 3D Visualization

What is Shingrix?

Shingrix is a recombinant herpes zoster vaccine designed to prevent shingles in adults. It consists of a purified form of the varicella-zoster virus (VZV) that has been engineered to stimulate an immune response without causing disease.

Clinical trials have shown Shingrix to be highly effective, with efficacy rates ranging from 97.6% for those aged 50-70 years to 91.3% for those over 70 years old.

How Does the 3D Visualization Work?

The 3D visualization provides a dynamic representation of Shingrix's efficacy across different age groups, allowing users to explore how effectiveness changes with age.

By orbiting and zooming in on the 3D model, you can see extruded bars representing the efficacy rates for each age group, which change as you adjust the age slider.

Efficacy Data and Antibody Titer Scaling

The simulation is based on clinical trial data showing that Shingrix has an efficacy rate of 97.6% in adults aged 50-70, 91.3% for those over 70, and 91.4% for those over 80.

Antibody titer scaling per dose is also incorporated into the model to show how immune response strength varies with each vaccination.

Long-Term Efficacy and Decay Models

The simulation includes long-term decay data, which shows how Shingrix's efficacy may change over time after the second dose.

This helps in understanding the need for booster doses or additional vaccines to maintain protection against shingles.

Frequently asked questions

Try it live

Everything above runs in your browser — open Shingrix Efficacy-by-Age Simulator (3D) and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.